Atara Biotherapeutics Inc

NASDAQ:ATRA 4:00:00 PM EDT

1.62

-0.15 (-8.48%)

7:57:12 PM EDT: $1.65 +0.03 (+1.85%)

Market Cap (Intraday)	158.71M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$5.36 Million
Adjusted EPS	-$0.64

See more estimates

10-Day MA	$1.97
50-Day MA	$2.60
200-Day MA	$3.77

See more pivots

Atara Biotherapeutics Inc Stock, NASDAQ:ATRA

2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, California 91320

United States of America

Phone: +1.805.623.4211

Number of Employees: 334

http://www.atarabio.com

Description

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.